Gluconeogenesis, lipogenesis, and HBV replication are commonly regulated by PGC-1α-dependent pathway

Hong Jhih Jhuang, Wei Hsiang Hsu, Kuan Ting Lin, Shih Lan Hsu, Feng Sheng Wang, Chen Kung Chou, Kuen Haur Lee, Ann Ping Tsou, Jin Mei Lai, Sheau Farn Yeh, Chi Ying F Huang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

PGC-1a, a major metabolic regulator of gluconeogenesis and lipogenesis, is strongly induced to coactivate Hepatitis B virus (HBV) gene expression in the liver of fasting mice. We found that 8-Br-cAMP and glucocorticoids synergistically induce PGC-1α and its downstream targets, including PEPCK and G6Pase. Also, HBV core promoter activity was synergistically enhanced by 8-Br-cAMP and glucocorticoids. Graptopetalum paraguayense (GP), a herbal medicine, is commonly used in Taiwan to treat liver disorders. Partially purified fraction of GP (named HH-F3) suppressed 8-Br-cAMP/glucocorticoid-induced G6Pase, PEPCK and PGC-1α expression and suppressed HBV core promoter activity. HH-F3 blocked HBV core promoter activity via inhibition of PGC-1α expression. Ectopically expressed PGC-1α rescued HH-F3-inhibited HBV surface antigen expression, HBV mRNA production, core protein levels, and HBV replication. HH-F3 also inhibited fatty acid synthase (FASN) expression and decreased lipid accumulation by down-regulating PGC-1α. Thus, HH-F3 can inhibit HBV replication, gluconeogenesis and lipogenesis by down-regulating PGC-1α. Our study indicates that targeting PGC-1α may be a therapeutic strategy for treatment of HBV infections. HH-F3 may have potential use for the treatment of chronic hepatitis B patients with associated metabolic syndrome.

Original languageEnglish
Pages (from-to)7788-7803
Number of pages16
JournalOncotarget
Volume6
Issue number10
Publication statusPublished - 2015

Fingerprint

Lipogenesis
Gluconeogenesis
Virus Replication
Hepatitis B virus
Glucocorticoids
Fatty Acid Synthases
Herbal Medicine
Liver
Chronic Hepatitis B
Virus Diseases
Hepatitis B Surface Antigens
Taiwan
Fasting
Therapeutics
Lipids
Gene Expression
Messenger RNA

Keywords

  • Gluconeogenesis
  • Graptopetalum paraguayense
  • HBV
  • Lipogenesis
  • PGC-1α

ASJC Scopus subject areas

  • Oncology

Cite this

Jhuang, H. J., Hsu, W. H., Lin, K. T., Hsu, S. L., Wang, F. S., Chou, C. K., ... Huang, C. Y. F. (2015). Gluconeogenesis, lipogenesis, and HBV replication are commonly regulated by PGC-1α-dependent pathway. Oncotarget, 6(10), 7788-7803.

Gluconeogenesis, lipogenesis, and HBV replication are commonly regulated by PGC-1α-dependent pathway. / Jhuang, Hong Jhih; Hsu, Wei Hsiang; Lin, Kuan Ting; Hsu, Shih Lan; Wang, Feng Sheng; Chou, Chen Kung; Lee, Kuen Haur; Tsou, Ann Ping; Lai, Jin Mei; Yeh, Sheau Farn; Huang, Chi Ying F.

In: Oncotarget, Vol. 6, No. 10, 2015, p. 7788-7803.

Research output: Contribution to journalArticle

Jhuang, HJ, Hsu, WH, Lin, KT, Hsu, SL, Wang, FS, Chou, CK, Lee, KH, Tsou, AP, Lai, JM, Yeh, SF & Huang, CYF 2015, 'Gluconeogenesis, lipogenesis, and HBV replication are commonly regulated by PGC-1α-dependent pathway', Oncotarget, vol. 6, no. 10, pp. 7788-7803.
Jhuang HJ, Hsu WH, Lin KT, Hsu SL, Wang FS, Chou CK et al. Gluconeogenesis, lipogenesis, and HBV replication are commonly regulated by PGC-1α-dependent pathway. Oncotarget. 2015;6(10):7788-7803.
Jhuang, Hong Jhih ; Hsu, Wei Hsiang ; Lin, Kuan Ting ; Hsu, Shih Lan ; Wang, Feng Sheng ; Chou, Chen Kung ; Lee, Kuen Haur ; Tsou, Ann Ping ; Lai, Jin Mei ; Yeh, Sheau Farn ; Huang, Chi Ying F. / Gluconeogenesis, lipogenesis, and HBV replication are commonly regulated by PGC-1α-dependent pathway. In: Oncotarget. 2015 ; Vol. 6, No. 10. pp. 7788-7803.
@article{fafaff13d0654ee4ab3a1c9e74c57f3e,
title = "Gluconeogenesis, lipogenesis, and HBV replication are commonly regulated by PGC-1α-dependent pathway",
abstract = "PGC-1a, a major metabolic regulator of gluconeogenesis and lipogenesis, is strongly induced to coactivate Hepatitis B virus (HBV) gene expression in the liver of fasting mice. We found that 8-Br-cAMP and glucocorticoids synergistically induce PGC-1α and its downstream targets, including PEPCK and G6Pase. Also, HBV core promoter activity was synergistically enhanced by 8-Br-cAMP and glucocorticoids. Graptopetalum paraguayense (GP), a herbal medicine, is commonly used in Taiwan to treat liver disorders. Partially purified fraction of GP (named HH-F3) suppressed 8-Br-cAMP/glucocorticoid-induced G6Pase, PEPCK and PGC-1α expression and suppressed HBV core promoter activity. HH-F3 blocked HBV core promoter activity via inhibition of PGC-1α expression. Ectopically expressed PGC-1α rescued HH-F3-inhibited HBV surface antigen expression, HBV mRNA production, core protein levels, and HBV replication. HH-F3 also inhibited fatty acid synthase (FASN) expression and decreased lipid accumulation by down-regulating PGC-1α. Thus, HH-F3 can inhibit HBV replication, gluconeogenesis and lipogenesis by down-regulating PGC-1α. Our study indicates that targeting PGC-1α may be a therapeutic strategy for treatment of HBV infections. HH-F3 may have potential use for the treatment of chronic hepatitis B patients with associated metabolic syndrome.",
keywords = "Gluconeogenesis, Graptopetalum paraguayense, HBV, Lipogenesis, PGC-1α",
author = "Jhuang, {Hong Jhih} and Hsu, {Wei Hsiang} and Lin, {Kuan Ting} and Hsu, {Shih Lan} and Wang, {Feng Sheng} and Chou, {Chen Kung} and Lee, {Kuen Haur} and Tsou, {Ann Ping} and Lai, {Jin Mei} and Yeh, {Sheau Farn} and Huang, {Chi Ying F}",
year = "2015",
language = "English",
volume = "6",
pages = "7788--7803",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "10",

}

TY - JOUR

T1 - Gluconeogenesis, lipogenesis, and HBV replication are commonly regulated by PGC-1α-dependent pathway

AU - Jhuang, Hong Jhih

AU - Hsu, Wei Hsiang

AU - Lin, Kuan Ting

AU - Hsu, Shih Lan

AU - Wang, Feng Sheng

AU - Chou, Chen Kung

AU - Lee, Kuen Haur

AU - Tsou, Ann Ping

AU - Lai, Jin Mei

AU - Yeh, Sheau Farn

AU - Huang, Chi Ying F

PY - 2015

Y1 - 2015

N2 - PGC-1a, a major metabolic regulator of gluconeogenesis and lipogenesis, is strongly induced to coactivate Hepatitis B virus (HBV) gene expression in the liver of fasting mice. We found that 8-Br-cAMP and glucocorticoids synergistically induce PGC-1α and its downstream targets, including PEPCK and G6Pase. Also, HBV core promoter activity was synergistically enhanced by 8-Br-cAMP and glucocorticoids. Graptopetalum paraguayense (GP), a herbal medicine, is commonly used in Taiwan to treat liver disorders. Partially purified fraction of GP (named HH-F3) suppressed 8-Br-cAMP/glucocorticoid-induced G6Pase, PEPCK and PGC-1α expression and suppressed HBV core promoter activity. HH-F3 blocked HBV core promoter activity via inhibition of PGC-1α expression. Ectopically expressed PGC-1α rescued HH-F3-inhibited HBV surface antigen expression, HBV mRNA production, core protein levels, and HBV replication. HH-F3 also inhibited fatty acid synthase (FASN) expression and decreased lipid accumulation by down-regulating PGC-1α. Thus, HH-F3 can inhibit HBV replication, gluconeogenesis and lipogenesis by down-regulating PGC-1α. Our study indicates that targeting PGC-1α may be a therapeutic strategy for treatment of HBV infections. HH-F3 may have potential use for the treatment of chronic hepatitis B patients with associated metabolic syndrome.

AB - PGC-1a, a major metabolic regulator of gluconeogenesis and lipogenesis, is strongly induced to coactivate Hepatitis B virus (HBV) gene expression in the liver of fasting mice. We found that 8-Br-cAMP and glucocorticoids synergistically induce PGC-1α and its downstream targets, including PEPCK and G6Pase. Also, HBV core promoter activity was synergistically enhanced by 8-Br-cAMP and glucocorticoids. Graptopetalum paraguayense (GP), a herbal medicine, is commonly used in Taiwan to treat liver disorders. Partially purified fraction of GP (named HH-F3) suppressed 8-Br-cAMP/glucocorticoid-induced G6Pase, PEPCK and PGC-1α expression and suppressed HBV core promoter activity. HH-F3 blocked HBV core promoter activity via inhibition of PGC-1α expression. Ectopically expressed PGC-1α rescued HH-F3-inhibited HBV surface antigen expression, HBV mRNA production, core protein levels, and HBV replication. HH-F3 also inhibited fatty acid synthase (FASN) expression and decreased lipid accumulation by down-regulating PGC-1α. Thus, HH-F3 can inhibit HBV replication, gluconeogenesis and lipogenesis by down-regulating PGC-1α. Our study indicates that targeting PGC-1α may be a therapeutic strategy for treatment of HBV infections. HH-F3 may have potential use for the treatment of chronic hepatitis B patients with associated metabolic syndrome.

KW - Gluconeogenesis

KW - Graptopetalum paraguayense

KW - HBV

KW - Lipogenesis

KW - PGC-1α

UR - http://www.scopus.com/inward/record.url?scp=84928390578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928390578&partnerID=8YFLogxK

M3 - Article

C2 - 25762623

AN - SCOPUS:84928390578

VL - 6

SP - 7788

EP - 7803

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 10

ER -